Live
- DEO suspends teacher accused of sexual assault
- PM ‘cursing’ Congress out of despair: Maharashtra Cong Chief
- Applications are invited for Junior Colleges Scheme District Scheduled Castes Development Officer Ramlal
- A nomination was filed on the second day for the Nagar Kurnool parliamentary seat
- SP Gaikwad inspected the Telangana Amarnath Saleswaram Jatara yatra arrangements
- Rahul Gandhi's decision to contest from Wayanad shows 'lack of confidence': BJP President Nadda
- IPL 2024: Delhi bowlers will go after all of SRH’s top-order batters, says head coach Ricky Ponting
- At Amroha rally, PM Modi sends out ‘meaningful’ message for Muslims and Hindus
- Tripura records highest 79.83 pc voter turnout in Northeast
- The government has to clear the confusion
WHO nod for Covaxin expected soon: Centre
Covaxin
World Health Organisation's (WHO) approval for emergency use authorization (EUA) to Covid-19 vaccine Covaxin, developed by Hyderabad-based Bharat Biotech, is expected soon, the Union Health Ministry said on Friday
New Delhi: World Health Organisation's (WHO) approval for emergency use authorization (EUA) to Covid-19 vaccine Covaxin, developed by Hyderabad-based Bharat Biotech, is expected soon, the Union Health Ministry said on Friday.
Union Minister of State for Health Bharati Pravin Pawar said the expected WHO's decision, which earlier was reportedly delayed, likely by October 5.
Bharat Biotech is expected to give a presentation on vaccine's safety and efficacy data of clinical trials (phase 1-3 trial results and post marketing) and risk management plans and other implementation considerations.
Bharat Biotech recently said it has submitted all the data pertaining to Covaxin to the WHO for EUL and is awaiting feedback from the global health watchdog. Based on the assessments of the SAGE working group, WHO will then consider the available pieces of evidence to determine EUA. The Phase-3 clinical trials of Covaxin demonstrated an efficacy rate of 77.8 per cent. All the relevant trial data has been submitted to WHO for EUL, and all clarifications sought by the UN health agency have been responded to, Bharat Biotech said.
Covaxin is one of the six vaccines that have received emergency use authorisation from India's drug regulator and is being used in the nationwide inoculation programme, along with Covishield and Sputnik V.
